Nasdaq

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
MarketWatch

Eli Lilly's Emgality gets FDA approval for episodic cluster headaches

Eli Lilly & Co. said Wednesday Emgality injection was approved by the U.S. Food and Drug Administration for the treatment of episodic cluster headache in adults. Lilly said Emgality is the first and ...
Business Insider

Emgality® (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...
MarketWatch

Eli Lilly says FDA has approved new migraine drug Emgality

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...
Business Insider

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
BioWorld

Emgality's FDA approval makes it only CGRP inhibitor to reduce cluster headache frequency

The FDA has approved Indianapolis-based Eli Lilly and Co.'s Emgality (galcanezumab-gnlm) solution (300 mg) for injection for treating episodic cluster headache in adults, making it the first and only ...
Nasdaq

Lilly's Emgality Gets FDA Approval for Cluster Headache

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
FiercePharma

NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...
Healio

FDA approves Emgality for migraine prevention

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...

Migraine prevention drug Emgality put on the Pharmaceutical Benefits Scheme, now hundreds of dollars cheaper

From June 1, the migraine prevention drug Emgality has been expanded on the Pharmaceutical Benefits Scheme, making it ...
FiercePharma

Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study

When the FDA awarded Biohaven Pharmaceuticals’ migraine med Nurtec ODT with a second indication last month, the company paraded the drug as the only option to both prevent and treat migraines. Now, ...